A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

← catalyst calendar

NCT07415954 · readout in 380 d

Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

270estimated

Sites

Countries

Croatia, Hungary, Japan +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-17

actual

When the study began enrolling

Primary completion

2027-09-03

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-10-01

estimated

The whole study's end, after follow-up

First posted

2026-02-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Diabetes Mellitus, Type 2

Interventions

Drug: NNC0662-0419
Drug: Semaglutide
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Change in glycated haemoglobin (HbA1c) (week 16)

measured From baseline (week 0) to week 16

Change in HbA1c (week 28)

measured From baseline (week 0) to week 28

Change in HbA1c (week 40)

measured From baseline (week 0) to week 40

Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed